Emerging treatments are expected to help fill the need for safer and more effective therapies for atopic dermatitis (AD). Both systemic and topical treatments are needed to provide full and complete treatment for patients with AD. Targeting the specific axis or axes that control AD may contribute to developing personalized approaches to treatment
Dr. Mark Lebwohl talks about the FDA’s approval of the anti-interleukin-17 receptor monoclonal antibody brodalumab (Siliq, Valeant Pharmaceuticals) for treatment of adults with moderate-to-severe plaque psoriasis.
In skin of color, psoriasis can be tough to spot, and it carries a broader differential diagnosis. Darker-skinned patients may not know that they can develop psoriasis, or the importance of seeking treatment early.
Stepwise introduction of egg (starting with a low dose, which is then increased), along with aggressive treatment of atopic dermatitis (AD), is a safe and effective way to prevent hen’s egg allergy in high-risk infants, a study in Japan showed.